embecta announces changes to Board of Directors
embecta (Nasdaq: EMBC) announced board changes on November 17, 2025. Director David J. Albritton resigned effective immediately for personal reasons, and Non-Executive Chairman LTG (Ret.) David F. Melcher will not stand for re-election and will retire at embecta’s 2026 annual stockholder meeting. Both directors served on the Board since its 2022 inception.
The Board expects to appoint Devdatt “Dev” Kurdikar as Chairman and Dr. Claire Pomeroy as Lead Independent Director effective upon Melcher’s departure. The Corporate Governance and Nominating Committee will evaluate desired independent director expertise and recommend potential replacements.
embecta (Nasdaq: EMBC) ha annunciato cambiamenti nel consiglio il 17 novembre 2025. Il direttore David J. Albritton si è dimesso con effetto immediato per motivi personali e il presidente non esecutivo LTG (Ret.) David F. Melcher non si ricandiderà e si ritirerà all’assemblea annuale degli azionisti di embecta nel 2026. Entrambi i direttori hanno fatto parte del Consiglio sin dalla sua nascita nel 2022.
Il Consiglio prevede di nominare Devdatt “Dev” Kurdikar come Presidente e Dr. Claire Pomeroy come Direttore Indipendente Principale a seguito della partenza di Melcher. Il Comitato di Governance aziendale e Nomine valuterà le competenze desiderate di un direttore indipendente e proporrà potenziali sostituzioni.
embecta (Nasdaq: EMBC) anunció cambios en la junta directiva el 17 de noviembre de 2025. El director David J. Albritton presentó su renuncia con efecto inmediato por motivos personales, y el presidente no ejecutivo LTG (ret.) David F. Melcher no se postulará para la reelección y se retirará en la reunión anual de accionistas de 2026 de embecta. Ambos directores han formado parte de la Junta desde su inicio en 2022.
La Junta espera nombrar a Devdatt “Dev” Kurdikar como Presidente y a la Dra. Claire Pomeroy como Directora Independiente Principal en funciones a partir de la salida de Melcher. El Comité de Gobernanza Corporativa y Nombramientos evaluará las habilidades deseadas de un director independiente y recomendará posibles reemplazos.
embecta (나스닥: EMBC)는 2025년 11월 17일 이사회 변경을 발표했다. 개인 사유로 즉시 효력을 갖고 사임한 다윗 J. 알브리턴 이사는 즉시 사임했고, 비상근 의장 LTG(은퇴) 데이비드 F. 멜처는 재선에 출마하지 않으며 embecta의 2026년 연례 주주총회에서 은퇴한다. 두 이사는 2022년 이사회 창립 이래 이사회에서 재직해 왔다.
이사회는 멜처의 떠남에 따라 Devdatt “Dev” Kurdikar를 의장으로, Dr. Claire Pomeroy를 선임독립 이사로 임명할 것으로 예상한다. 기업지배구조 및 지명위원회는 독립 이사의 필요한 전문성을 평가하고 잠재적 후임자를 권고할 것이다.
embecta (Nasdaq : EMBC) a annoncé des changements au conseil d'administration le 17 novembre 2025. Le directeur David J. Albritton a démissionné avec effet immédiat pour des raisons personnelles, et le président non exécutif LTG (Ret.) David F. Melcher ne sollicitera pas de nouveau mandat et prendra sa retraite lors de l’assemblée annuelle des actionnaires d’embecta en 2026. Les deux administrateurs font partie du conseil depuis sa création en 2022.
Le conseil prévoit de nommer Devdatt “Dev” Kurdikar en tant que président et Dr. Claire Pomeroy en tant que directrice principale indépendante à compter du départ de Melcher. Le Comité de gouvernance d’entreprise et de nomination évaluera les compétences souhaitées pour un directeur indépendant et recommandera des remplacements potentiels.
embecta (Nasdaq: EMBC) gab Änderungen im Vorstand am 17. November 2025 bekannt. Direktor David J. Albritton trat aus persönlichen Gründen mit sofortiger Wirkung zurück, und der Nicht-Executive Chairman LTG (Ret.) David F. Melcher wird nicht erneut kandidieren und wird auf der Hauptversammlung der Aktionäre 2026 von embecta in den Ruhestand treten. Beide Direktoren gehören dem Vorstand seit dessen Gründung im Jahr 2022 an.
Der Vorstand plant, Devdatt “Dev” Kurdikar zum Vorsitzenden und Dr. Claire Pomeroy zur Lead Independent Director zu ernennen, wirksam mit Melchers Weggang. Der Corporate Governance and Nominating Committee wird die gewünschten Fachkenntnisse unabhängiger Direktoren bewerten und potenzielle Nachfolger empfehlen.
embecta (بورصة ناسداك: EMBC) أعلنت عن تغييرات في المجلس يوم 17 نوفمبر 2025. استقال المدير ديفيد ج. ألبريتون لأسباب شخصية مع تأثير فوري، ولن يترشّح رئيس مجلس الإدارة غير التنفيذي LTG (Ret.) ديفيد ف. ميلشر لإعادة الانتخاب وسيتقاعد في اجتماع المساهمين السنوي لعام 2026 لشركة embecta. كان كل من المديرين الاثنين عضوين في المجلس منذ تأسيسه في عام 2022.
يتوقع المجلس تعيين Devdatt “Dev” Kurdikar كرئيس مجلس الإدارة وDr. Claire Pomeroy كمدير مستقل رئيسي اعتباراً من مغادرة ميلشر. ستقيّم لجنة الحوكمة المؤسسية والتعيين المهارات المطلوبة لمدير مستقل وتقترح خلفاء محتملين.
- Immediate appointment plan: Kurdikar to become Chairman
- Lead independent director named: Pomeroy effective on departure
- Board continuity: both directors served since 2022
- Albritton resigned effective immediately
- Chairman Melcher will retire at the 2026 annual meeting
- Board will need to replace two directors and assess expertise
PARSIPPANY, N.J., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medical supplies company, today announced that David J. Albritton, a member of the Board of Directors (the “Board”) of embecta, has resigned from the Board due to personal reasons, effective immediately. In addition, LTG (Ret.) David F. Melcher, Non-Executive Chairman of the Board, has informed the company that he will not stand for re-election at embecta’s 2026 annual stockholder meeting and will retire from the Board at that time due to several commitments outside of his service to the Company. Both have been Directors since the Board’s inception in 2022.
“On behalf of the entire Board of Directors and the global embecta team, I want to thank both of them for lending their experience, wisdom and guidance as we launched a new company in a dynamic environment,” said Devdatt “Dev” Kurdikar, President and Chief Executive Officer. “Each has brought invaluable leadership experience that helped us successfully navigate the unique challenges of separating and standing up embecta. In particular, I wish to thank David Albritton for his contributions in shaping our corporate identity and communications efforts as we worked to establish embecta and provide an unflinching focus on care for people living with diabetes.”
Mr. Kurdikar added, “I personally have benefited immensely from Dave Melcher’s leadership and mentoring since his appointment as Chair of our Board. His counsel and support as we executed multiple complex initiatives in a challenging macroenvironment have been an integral part of our ability to execute all our stand-up programs. I am deeply grateful for Dave’s service and contributions to our company.”
“It has been a privilege to serve as Chairman of such a distinguished and collegial Board of Directors,” said LTG Melcher. “As embecta transitions from its initial standup phase to one where we begin to seed growth, the company’s strategic direction and priorities are clear. I’m confident that the ongoing stewardship of Dev and the rest of the Board will enable embecta to continue to prioritize the needs of our customers, employees and shareholders.”
The Board expects to appoint Mr. Kurdikar as Chairman of the Board, and Dr. Claire Pomeroy, who has also served on the Board since its inception, as Lead Independent Director, each effective upon LTG Melcher's departure from the Board. The Corporate Governance and Nominating Committee will assess what expertise may be desired from future independent directors in view of the strategic direction of the company and accordingly recommend any potential replacements for the departing Directors.
About embecta
embecta is a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medical supplies company, helping to improve lives through innovative solutions, partnerships, and the passion of approximately 2,000 employees around the globe. For more information, visit embecta.com or follow our social channels on LinkedIn, Facebook, and Instagram.
Safe Harbor Statement Regarding Forward-Looking Statements
This press release contains express or implied "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995 and other securities laws. These forward-looking statements concern our current expectations regarding strategic direction and priorities and expectations regarding our Board composition. These forward-looking statements are subject to various known and unknown risks, uncertainties and other factors, and you should not rely upon them except as statements of our present intentions and of our present expectations, which may or may not occur. When we use words such as “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “pursue,” “will,” “goal” or similar expressions, we are making forward-looking statements. Although we believe that our forward-looking statements are based on reasonable assumptions, our expected results may not be achieved, and actual results may differ materially from our expectations. In addition, important factors that could cause actual results to differ from expectations include, among others, the risks described in our periodic reports filed with the Securities and Exchange Commission, including under the caption “Risk Factors” in our most recent Annual Report on Form 10-K, as further updated by our Quarterly Reports on Form 10-Q we have filed or will file hereafter. Except as required by law, we undertake no obligation to update any forward-looking statements appearing in this release.
| Contacts: | |
| Media | Investors |
| Christian Glazar | Pravesh Khandelwal |
| Sr. Director, Corporate Communications | VP, Head of Investor Relations |
| 908-821-6922 | 551-264-6547 |
| Contact Media Relations | Contact IR |
FAQ
Who resigned from embecta's Board on November 17, 2025?
When will LTG (Ret.) David F. Melcher leave embecta's Board (EMBC)?
Who will become embecta's Chairman after Melcher departs (EMBC)?
Who will serve as embecta's Lead Independent Director after the change (EMBC)?
How will embecta replace the departing directors on the Board (EMBC)?
